Leqembi vs Vyepti
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Leqembi | US Vyepti | |
|---|---|---|
| Generic name | lecanemab | eptinezumab |
| Drug class | Anti-Amyloid Monoclonal Antibody | Anti-CGRP Monoclonal Antibody |
| Treats | Early Alzheimer's disease | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Eisai | Lundbeck |
| Year approved | 2023 | 2020 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | — | — |
| Common side effects | Brain swelling (ARIA), Brain bleeding (ARIA), Infusion reactions, Headache | Stuffy nose and sore throat, Allergic reactions, Fatigue |
Frequently asked questions
Is Leqembi or Vyepti better?
Neither is universally "better." Leqembi (lecanemab) and Vyepti (eptinezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Leqembi and Vyepti?
Leqembi is a Anti-Amyloid Monoclonal Antibody made by Eisai, while Vyepti is a Anti-CGRP Monoclonal Antibody made by Lundbeck. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Leqembi has the larger estimated TV advertising budget of the two.